Key Highlights
- RBC Capital increased Astera Labs (ALAB) price target to $250 from $225, maintaining its Outperform rating
- The bullish outlook hinges on anticipated Scorpio-X switch revenue linked to Trainium3, expected to begin in Q3 2026
- RBC forecasts Scorpio switch revenue will triple from $130M in 2025 to $390M in 2026
- UBS launched coverage with a Neutral stance and $180 price target, pointing to switching market competition
- Q4 2025 results showed ALAB delivered $0.58 EPS, exceeding the $0.51 consensus, while revenue climbed 92% YoY to $270.6M
Astera Labs experienced a noteworthy Monday as two separate analyst firms weighed in on the stock — though their perspectives diverged considerably.
Astera Labs, Inc. Common Stock, ALAB
RBC Capital elevated its price objective for Astera Labs to $250 from the previous $225, while reaffirming its Outperform rating. Shares were changing hands near $175.80 during trading, representing approximately a 10% gain for the session.
The optimistic thesis from RBC revolves around Scorpio-X, Astera’s upcoming switch technology. Analysts anticipate that Trainium3-connected Scorpio-X deployments will begin generating revenue by the third quarter of 2026, creating additional revenue streams per XPU unit.
RBC’s financial models show total Scorpio switch revenue expanding from $130 million in 2025 to $390 million in 2026 — effectively tripling within twelve months.
The updated $250 price objective reflects 74 times RBC’s calendar 2027 earnings per share forecast of $3.37. Previously, the firm applied a 67x earnings multiple. RBC cited several new product launches, an expansive total addressable market, anticipated revenue expansion of 40–50%, and gross profit margins exceeding 70% as rationale for the elevated valuation multiple.
Astera’s current gross margin stands at 75.69%, accompanied by 115% revenue growth over the trailing twelve-month period.
UBS Adopts a More Reserved Stance
UBS likewise launched coverage on ALAB Monday, though with a Neutral rating and $180 price target — barely above the stock’s trading level at the time.
Analyst Natalia Winkler recognized that the company has established a legitimate presence in AI networking infrastructure over a five-year period, demonstrating solid execution with retimer products and cultivating relationships beyond AWS, its primary customer. Astera introduced its retimer offerings in 2019 and has subsequently gained traction with additional hyperscale clients.
UBS anticipates 2027 revenues running 4% ahead of Wall Street consensus, powered by retimers and the PCIe/UA Link switching product lineup. However, for 2028, UBS models come in 3% below consensus, highlighting intensifying competition in the switching segment as a potential obstacle.
Valuation represents the primary concern for UBS. Astera commands a high-40s forward 2027 price-to-earnings ratio, significantly exceeding AI networking sector peers. The firm indicated it identifies more attractive risk-reward opportunities in other networking companies.
Recent Quarterly Performance Supports Growth Narrative
Both analyst perspectives are informed by robust recent financial results. Astera delivered Q4 2025 earnings per share of $0.58, surpassing the consensus estimate of $0.51 by nearly 14%.
Quarterly revenue reached $270.6 million, marking a 92% increase compared to the prior year period.
According to InvestingPro data, twelve analysts have increased their earnings projections for the coming period.
The equity has generated a 223% return over the past twelve months. Notwithstanding this substantial appreciation, ALAB’s PEG ratio of 0.47 indicates the valuation may be more reasonable than the headline price-to-earnings multiple of 143 suggests — particularly when adjusting for growth rates.
RBC’s $250 price target represents approximately 42% potential upside from present levels. UBS’s $180 target offers minimal upside from the current trading range.
